Traditional biomarkers for the prognosis, diagnosis, and monitoring of liver cancer, such as alpha-fetoprotein, have limitations not only in terms of the underlying mechanisms at the surveillance stage, but also in predicting late clinical outcomes. This evidence concerns the gene AFP and liver cancer.